First Non-Hormonal Treatment for Hot Flashes Approved by FDA
In an unexpected move, the FDA approved Brisdelle (paroxetine), the first non-hormonal treatment for hot flashes associated with menopause, in spite of a recent panel’s recommendation against the drug.
In an unexpected move, the FDA approved Brisdelle (paroxetine), the first non-hormonal treatment for hot flashes associated with menopause, in spite of a recent panel’s recommendation against the drug.
Brisdelle contains 7.5 mg of paroxetine, a selective serotonin reuptake inhibitor (SSRI) that is used at higher doses to treat depression and anxiety disorders. Two randomized, controlled, double-blind studies in women with moderate to severe hot flashes showed that Brisdelle reduced the frequency and severity of hot flashes.
There was a low occurrence of side effects, most commonly nausea. Because paroxetine is also used to treat depression, it will carry a Boxed Warning about the possibility of the medication increasing suicidality in children and young adults.
Hot flashes affect nearly 75% of women in menopause. Historically, hormone therapy with estrogen has been the only approved pharmacologic treatment, but its side effects and risk profile made it unacceptable for many patients.
Adiponectin found a key biomarker for cardiometabolic risk in postmenopausal women
February 27th 2025A new study highlights adiponectin’s strong links to obesity and metabolic health markers, suggesting its potential as an effective tool for predicting and managing cardiometabolic risk in perimenopausal women.
Read More
